DeepBlueEquity1 Posted - 1 week ago

$ONCO DD suggests an asset sale or a company restructure is likely... partner and major creditor Veru Inc $VERU may be interested in ONCO subsidiary Proteomedix AG which recently signed a license deal with Labcorp $LH for the Proclarix® Blood Test to Detect Prostate Cancer

DeepBlueEquity1 Posted - 1 week ago

$ONCO Onconetix with it's acquisition of Proteomedix Inc has Issued Labcorp $LH Exclusive License for Proclarix® Blood Test to Detect Prostate Cancer https://www.businesswire.com/news/home/20230411005085/en/Proteomedix-Agrees-to-Issue-Labcorp-Exclusive-License-for-Proclarix

Sam201 Posted - 2 weeks ago

$CRL $LH $NOTV great finish by notv! I said this before n saying again - still undervalued!

Thestocktraderhubzee Posted - 2 weeks ago

$LH Evercore ISI Group Maintains In-Line on Labcorp Holdings, Raises Price Target to $215

Stock_Titan Posted - 2 weeks ago

$LH NOWDiagnostics Secures $22.5 Million in Series B Funding https://www.stocktitan.net/news/LH/now-diagnostics-secures-22-5-million-in-series-b-1ckycd86sc3h.html

Thestocktraderhubzee Posted - 2 weeks ago

$LH Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $261

Stock_Titan Posted - 3 weeks ago

$LH Labcorp to Announce Second Quarter Financial Results on August 1, 2024 https://www.stocktitan.net/news/LH/labcorp-to-announce-second-quarter-financial-results-on-august-1-7io567ixnvjc.html

Stocksrunner Posted - 1 month ago

$LH Laboratory Corporation of America reported encouraging results from its CV5 assays, with significant lithium mineralization over wide intervals. These results are ahead of a resource update expected in Q3, driving the stock up.

Sam201 Posted - 1 month ago

$NOTV way undervalued compared to peers $CRL n $LH! Overreaction to $35 million fine! This should go up but shorts are controlling this currently and without any PR it may dip more!

DonCorleone77 Posted - 1 month ago

$LH Labcorp launches Global Trial Connect to accelerate clinical trials Labcorp announced the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted - investigator sites. "The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster," said Jon DiVincenzo, EVP and President, Central Laboratories and International at Labcorp. "As the world's leading central laboratory, Labcorp is dedicated to improving the pace of clinical trials focusing on the investigator site experience from study initiation to patient recruitment and data collection."

Stock_Titan Posted - 1 month ago

$LH Labcorp Launches Global Trial Connect to Accelerate Clinical Trials https://www.stocktitan.net/news/LH/labcorp-launches-global-trial-connect-to-accelerate-clinical-pj6h76t3s8dt.html

Stock_Titan Posted - 1 month ago

$LH Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio https://www.stocktitan.net/news/LH/labcorp-announces-new-strategic-service-offerings-within-precision-m1mkomgrv215.html

hiphoppier Posted - 2 months ago

$LH $180 been the longer-term bottom range here....

Aigner_Andreas Posted - 2 months ago

TD SELL $LH at 210.59, Supp 200.25 Resis 213.21 R6 HiLo 59% T1Y 293 buy 1.9 DIV 1.25% #Laboratory #stocks #trading #finance #market

Chark Posted - 2 months ago

$LH Haven’t looked at this in awhile. The chart looks so ugly I thought it had split. 😂

InsiderPeek Posted - 2 months ago

$LH Chief Legal Officer Van Der Vaart Sandra D sold 2k shares for $421.7k (ownership down 26.19%) insiderpeek.com/company/LH

Stock_Titan Posted - 2 months ago

$LH Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy https://www.stocktitan.net/news/LH/labcorp-introduces-first-trimester-screening-test-to-assess-mxhmxvezmcqa.html

lowfloatscambuster Posted - 2 months ago

@IOMASS The market is telling you it doesn’t believe that. Every time $LH drops a new adjacent diagnostic test to QTRX, stock gets destroyed- it happened last year around this https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-new-test-accelerate-path-diagnosis-alzheimers And QTRX management has been woefully inept at managing the message, that is 100% a contributing factor to the EV of this company being a pathetic $300 million. I think they have 6 months MAX left to prove that they can capitalize on the AD oportunity as a standalone company. But if you again hear that diagnostic revs are “immaterial” and not included in guidance when they report Q2 in Aug, look out below. At this point, if there is a strategic offering them $30/shr, they need to take that deal immediately. It’s not out of the question - the technology is real and it can be valuable.

Stock_Titan Posted - 2 months ago

$LH $NVTAQ Invitae Receives Court Approval for Sale to Labcorp https://www.stocktitan.net/news/LH/invitae-receives-court-approval-for-sale-to-huihfjskcx24.html

DonCorleone77 Posted - 2 months ago

$LH Geneoscopy to launch ColoSense in collaboration with Labcorp after FDA approval Geneoscopy announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC. Designated as a Breakthrough Device by the FDA, ColoSense is the first noninvasive colorectal cancer screening test to provide a dynamic view of disease activity by using RNA biomarkers. RNA biomarkers are not subject to age-related methylation patterns that can lead to variability in test performance across different age groups. FDA approval of ColoSense is a significant step in making this important screening tool available to patients. Geneoscopy is working with payors, professional societies, and advocacy partners to support a commercial launch later this year or early in 2025 to ensure patients have timely access to ColoSense to support CRC screening. Geneoscopy will launch ColoSense in collaboration with Labcorp (LH).

Stock_Titan Posted - 2 months ago

$LH FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test https://www.stocktitan.net/news/LH/fda-approves-colo-sense-geneoscopy-s-noninvasive-multi-target-stool-12jawwubaxg6.html

smartkarma Posted - 2 months ago

$LH | Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers "Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for..." - Baptista Research (Baptista Research) Key Points:Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%. Read more: https://www.smartkarma.com/insights/laboratory-corporation-of-america-labcorp-will-the-acquisition-of-invitae-be-a-game-changer-major-drivers

insiderbuyingselling Posted - 2 months ago

$LH new insider selling: 500 shares. http://insiderbuyingselling.com/?t=LH

Lectin_Pectin Posted - 2 months ago

$INBS very bullish article here. Great info and synopsis. https://talkmarkets.com/content/stocks--equities/intelligent-bio-solutions-fingerprint-drug-screening-technology-poised-for-massive-growth?post=442811 They might actually give those $LH and $DGX urine tests a run for their money!!

insiderbuyingselling Posted - 2 months ago

$LH new insider selling: 2439 shares. http://insiderbuyingselling.com/?t=LH

WhisperNumber Posted - 04/30/24

$CVS #earnings before open Wed, the expectation from the WhisperNumber community is $1.81, 10c ahead of analyst estimates. Earnings came in $0.04 ahead of the whisper last quarter. 58% beat rate. Implied movement +/-4.3%. https://www.whispernumber.com #options $CI $LH

Stocksrunner Posted - 04/29/24

🏗️ Sector Spotlight: $DGX $LH - Quest Diagnostics, LabCorp climb following FDA testing oversight rule. Psychedelic drug developers could benefit from NIH funding for chronic pain.

briefingcom Posted - 04/29/24

$LH: Laboratory Corp receives FDA approval for first companion diagnostic for use with Pfizer's (PFE) newly approved gene therapy to treat patients with Hemophilia B https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240429070728LH&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 04/29/24

$LH $PFE Labcorp: FDA approves nAbCyte Anti-AAVRh74var HB-FE Assay Labcorp (LH) announced the U.S. FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient eligibility for treatment with BEQVEZ, Pfizer's (PFE) recently FDA-approved hemophilia B gene therapy. The nAbCyte cell-based neutralizing antibody assay is a component of Pfizer's program to target recombinant adeno-associated virus-based gene therapies to the appropriate patient population. Before infusion with BEQVEZ, patients will require testing for preexisting anti-AAVRh74var antibodies. Labcorp's nAbCyte cell-based neutralizing antibody assay will allow for the accurate detection of preexisting neutralizing antibodies, which could impact patient safety and/or efficacy of the one-time treatment.

Stock_Titan Posted - 04/29/24

$LH Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B https://www.stocktitan.net/news/LH/labcorp-receives-fda-approval-for-first-companion-diagnostic-for-use-lg4gwwht3500.html